Environmental sustainability in asthma: reducing carbon footprint and medication wastage

Ming Ren Toh, Susan Ang, Gerald Xuan Zhong Ng, Ishita Goel, Kathy A. Low, Vivian Tan, Kheng Yong Ong, Ting Chan, Jun Tian Wu, Chun Fan Lee, Marcus Eng Hock Ong, David B. Matchar, Ngiap Chuan Tan, Chian Min Loo, Shao Wei Lam, Mariko Siyue KohAllergy 2025 · DOI

TL;DR

This study quantifies the carbon footprint of asthma inhalers in Singapore, revealing that ICS-LABA MDIs are the primary contributors. It also highlights significant medication wastage due to oversupply, particularly in primary care settings, and suggests strategies to mitigate both environmental impact and waste.

What Problem Does This Paper Address?

Asthma inhalers, while crucial for managing the condition affecting over 260 million people globally, contribute significantly to greenhouse gas emissions. Metered-dose inhalers (MDIs) are particularly problematic due to their hydrofluorocarbon (HFC) propellants, responsible for millions of tonnes of CO2e emissions annually. While the environmental impact of inhaler propellants is increasingly recognized, less is understood about the "avoidable" carbon footprint stemming from medication wastage and oversupply. This paper aims to bridge this knowledge gap by analyzing dispensing patterns, quantifying medication wastage, and identifying factors contributing to oversupply within a large healthcare network.

Methods

The researchers conducted a retrospective, observational study using anonymized data from Singapore's largest public healthcare network spanning from January 2015 to December 2019. They analyzed electronic medical, pharmacy, and administrative records to extract patient demographics, comorbidities, asthma severity (GINA steps), and site of care.

Key methodological aspects include:

  • Carbon Footprint Calculation: The study utilized pre-defined carbon footprint data (in kgCO2e per canister) for different inhaler types, based on their propellants.
  • Medication Wastage Quantification: Wastage was defined at the visit level as the number of inhalers dispensed in excess of the quantity required during each refill interval. This was calculated using the formula: Excess = Dispensed - (Refill interval × Prescribed daily dose / Doses per canister).
  • Medication Oversupply Measurement: At the patient level, oversupply was defined by a medication possession ratio (MPR) greater than 1.2. MPR was calculated as the total dispensed days (summed across all maintenance inhalers) divided by the follow-up period.
  • Statistical Analysis: Trends in prescriptions, carbon footprint, and wastage were analyzed over time. Multinomial regression was employed to identify associations between patient characteristics (demographics, comorbidities, GINA step, site of care) and medication oversupply.

Datasets

The study utilized data from the SingHealth Chronic Obstructive Pulmonary Disease (COPD) and Asthma Data Mart (SCDM), a comprehensive real-world database integrating electronic medical, pharmacy, and administrative records from a large Singaporean healthcare cluster. This dataset contained anonymized patient-level and visit-level information. No new benchmarks were introduced; the study leveraged existing real-world data.

Key Insights and Ideas

  • ICS-LABA MDIs Dominate Carbon Footprint: The study unequivocally identifies ICS-LABA MDIs as the largest contributors to the carbon footprint of asthma inhalers, a trend expected to continue.
  • Wastage is a Significant, Avoidable Problem: Beyond propellant emissions, a substantial amount of medication is dispensed in excess of need, leading to avoidable carbon emissions and resource waste.
  • Primary Care Settings Drive Oversupply: Patients managed in primary care settings are significantly more likely to receive oversupplied medications compared to those in specialist care, suggesting a need for targeted interventions.
  • GINA Step Influences Oversupply: Higher GINA treatment steps are associated with a lower likelihood of medication oversupply, potentially due to more intensive monitoring.
  • DPIs Offer a Greener Alternative (with caveats): Dry powder inhalers (DPIs) have a significantly lower carbon footprint than MDIs, but their effective use requires proper technique, which can be a challenge for some patients.

Key Results

  • Over 205,000 inhaler units were dispensed, contributing an estimated 1.54 million kgCO2e.
  • ICS-LABA MDIs accounted for over half of the total carbon emissions (846,102 kgCO2e).
  • Annual emissions from ICS-LABA MDIs nearly doubled from 2015 to 2019.
  • A total of 6,427 canisters were dispensed in excess of refill intervals, contributing 46,798 kgCO2e in avoidable emissions. Beclomethasone dipropionate MDIs were the largest contributors to this wasted footprint.
  • Approximately 24.4% of patients (1,956 individuals) were identified as having persistent medication oversupply (MPR > 1.2).
  • Patients in primary care settings were nearly twice as likely to be oversupplied (OR 1.93, 95% CI 1.49–2.51).

Limitations and Future Work

The authors acknowledge several limitations:

  • Incomplete Carbon Footprint: The study did not account for emissions from inhaler manufacturing, disposal, or other healthcare utilization aspects (e.g., clinic operations, patient commute). It also couldn't quantify discarded doses within used canisters.
  • Exclusion of Certain Inhalers: Long-acting muscarinic antagonist (LAMA) inhalers and single-inhaler triple therapies, primarily used for COPD at the time of the study, were not included.
  • Potential for Underestimation: The true burden of medication wastage might be greater than estimated, considering frequent regimen switches and excessive SABA use.

Future work could focus on:

  • Implementing interventions to reduce medication wastage and oversupply, particularly in primary care.
  • Exploring the feasibility and impact of switching suitable patients from ICS-LABA MDIs to DPIs.
  • Developing comprehensive strategies to minimize the carbon footprint of asthma care, balancing sustainability with optimal patient outcomes.
  • Further research into the economic and environmental impacts of inhaler disposal and manufacturing.

Summary updated

Abstract

ICS-LABA MDIs are the predominant source of inhaler-related carbon footprint, with additional contribution from excessive dispensation of inhalers.
BibTeX
@inproceedings{toh2025environmental,
  author = {Ming Ren Toh and Susan Ang and Gerald Xuan Zhong Ng and Ishita Goel and Kathy A. Low and Vivian Tan and Kheng Yong Ong and Ting Chan and Jun Tian Wu and Chun Fan Lee and Marcus Eng Hock Ong and David B. Matchar and Ngiap Chuan Tan and Chian Min Loo and Shao Wei Lam and Mariko Siyue Koh},
  title = {{Environmental sustainability in asthma: reducing carbon footprint and medication wastage}},
  booktitle = {Allergy},
  year = {2025},
  doi = {10.1186/s13223-025-00988-x},
}
Figure